Ward Medication Management Ward Medication Management Ward Medication Management Ward Medication Management
  • Home
  • About Us
  • Services
  • Partners
  • Careers
  • News
  • Knowledge Hub
  • Contact Us
  • Sign In
Ward Medication Management Ward Medication Management
  • Home
  • About Us
  • Services
  • Partners
  • Careers
  • News
  • Knowledge Hub
  • Contact Us
  • Sign In
Jan 12

Ward Clinical Pearl: 12 January 2017 – Drugs and tachycardia (Part 1)

  • January 12, 2017
  • Joanna Foy
  • No Comments
  • Clinical Pearls

Each week we will aim to bring out a concise email that provides 4-5 key pieces of information addressing a specific issue in clinical therapeutics.

 

This week: Drugs and tachycardia (Part 1)

Tachycardia is the generic term used to describe increased heart rate. In some cases tachycardia is mild and transient, but in other situations the issue can be persistent and clinically significant. Tachycardia is often defined as a resting heart rate of > 100 bpm, and persistently elevated heart rate is associated with a range of adverse clinical outcomes include myocardial infarction and cerebrovascular accidents. Some causes of tachycardia (e.g. Atrial Fibrillation, AF) warrant special consideration and will be considered separately elsewhere.

 

  • Tachycardia may be associated with the use of non-medicinal drugs, including those used in social contexts. Excessive use of alcohol and nicotine (even when used in medicinal products such as patches and lozenges), can cause a significantly increased heart rate.  The intake of large amounts of caffeine, which can occur after over consumption of coffee, tea, cola beverages or “energy drinks” can also contribute to tachycardia.
  • Some medications May contribute to tachycardia through indirect mechanisms. For example, occult gastrointestinal blood loss associated with agents such as anticoagulants and NSAIDs may result in anaemia, which in turn can drive tachycardia as a compensatory mechanism.
  • Similarly, fever or dehydration secondary to medications may also contribute to tachycardia.

 

Please consider these issues when preparing or interpreting RMMR reports or education sessions. Contributions of content or suggested topics are welcome and should be sent directly to chris@wardmm.com.au.

  • Facebook
  • Twitter
  • Tumblr
  • Pinterest
  • Google+
  • LinkedIn
  • E-Mail

About The Author

Leave a reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • Ward Clinical Pearl: 17 April 2018 – Methotrexate SC Injection
  • Ward Clinical Pearl: 10 April 2018 – Direct/Newer Anticoagulants Part 2
  • Ward Clinical Pearl: 3 April 2018 – Direct/Newer Anticoagulants Part 1
  • Ward MM Newsletter March 2018
  • Ward Clinical Pearl: 27 March 2018 – Updating Medicine Ingredients Names Part 2

Archives

  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015

Categories

  • Clinical Pearls
  • Company News
  • Newsletters

Meta

  • Log in
  • Entries RSS
  • Comments RSS
  • WordPress.org

© Ward Medication Management 2017 All Rights Reserved | Privacy Policy | Ethics Statement